Dermira secures raises funding for dermatology innovation

The company is aiming develop and commercialise innovative new therapies in dermatology.

Dermira has announced that it has managed to raise the $35 million (£22.5 million) needed to help fund innovation in dermatology.
The development-stage biotechnology company is looking to create and commercialise innovative new therapies within the sector.
It managed to source the funds in a Series B financing and related transaction which saw Maruho Co. Ltd, a leading dermatology company in Japan, join the investment programme at Dermira.
The firm has already been helped by benefactors such as Bay City Capital New Enterprise Associates and Canaan Partners.
Tom Wiggans, chief executive officer of Dermira, said: "This financing with the addition of Maruho and their expertise in global dermatology demonstrates Dermira’s continued progress in the development of innovative novel compounds in areas of high patient need."
Dermira is focused on developing new methods of dermatology therapies and the funding is set to go towards accelerating the company's robust pipeline which it hopes to bring to market.